<DOC>
	<DOCNO>NCT01565148</DOCNO>
	<brief_summary>- To assess safety repeat iCo-007 intravitreal injection treatment subject diabetic macular edema monotherapy combination ranibizumab laser photocoagulation - To assess change visual acuity retinal thickness OCT baseline month 8 month 12</brief_summary>
	<brief_title>A Randomized , Multi-center , Phase II Study Safety , Tolerability Bioactivity Repeated Intravitreal Injections iCo-007 Monotherapy Combination With Ranibizumab Laser Photocoagulation Treatment Diabetic Macular Edema ( iDEAL Study )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥18 year Have diabetes mellitus type I II ( insulin noninsulin dependent ) HbA1c ≥5.5 % HbA1c ≤13 % ; nonproliferative diabetic retinopathy , inactive proliferative diabetic retinopathy , proliferative diabetic retinopathy reasonable expectation panretinal photocoagulation require study followup period Have diabetic macular edema central subfield thickness ≥250 micron ( confirm Stratus TD OCT Have best correct visual acuity ( ETDRS ) Snellen equivalent 20/32 ≥20/320 , inclusive Be willing able sign approve write informed consent . If patient central nervous system disorder ( i.e . dementia ) allow him/her understand consent independently , patient allow join study Be able attend schedule study visit Women lactate pregnant willing use adequate contraception study period , appropriate Have macular perimacular edema secondary etiology diabetes Have concurrent retinal disease diabetic retinopathy Have additional ocular disease compromise visual acuity and/or interfere study assessment ; patient glaucoma deem stable ( intraocular pressure ≤ 25 mmHg screen ) medication status post surgery , may participate study Participant history prior par plana vitrectomy Subjects significant cataract posterior capsular opacification may need intervention within one year vitreous opacity hinder study assessment ( i.e.fundus examination ) require intervention within year Subjects DME severe capillary nonperfusion ( avascular zone diameter &gt; 1,000 micron ) Have allergy fluorescein dye Have terminal renal disease ( active kidney dialysis ) , cerebral vascular accident ( include TIA ) , myocardial infarction congestive heart disease within 6 month study enrollment , liver damage ( 2x upper limit normal range AST , ALT total bilirubin ) . Patients may receive renal transplant past stable renal function , may participate study Subjects systolic blood pressure high 180 mm Hg diastolic 100 mm Hg , without antihypertensive treatment Have history panretinal photocoagulation ( PRP ) study eye within 3 month study entry likely PRP study eye study participation Had macular photocoagulation ocular surgery within 3 month study entry study eye Received intraocular periocular injection steroid study eye ( e.g. , triamcinolone ) within 3 month study entry antiangiogenic drug ( pegaptanib sodium , ranibizumab , bevacizumab , VEGFTRAP , protein kinase C inhibitor , etc . ) within 2 month study entry ; history usage topical systemic steroid within 3 month study entry exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>DME</keyword>
</DOC>